Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
October 18, 2022 10:30 ET
|
Biofrontera Inc.
Four Posters Highlighting Results from Investigator-Initiated and Company-Sponsored Research with Ameluz to be Presented WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-PDT Through October 2040
March 14, 2022 09:25 ET
|
Biofrontera Inc.
WOBURN, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
February 01, 2022 08:47 ET
|
Biofrontera Inc.
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is...
Biofrontera AG announces initiation of clinical studies
November 16, 2021 09:01 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two...
Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court
September 22, 2020 12:02 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in...
Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds
July 27, 2020 13:15 ET
|
Biofrontera AG
Leverkusen, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Supervisory...
Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting
April 16, 2020 10:00 ET
|
Biofrontera AG
Leverkusen, Germany, April 16, 2020 (GLOBE NEWSWIRE) -- The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the Company...
Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz® in Poland with medac GmbH Sp. z o.o.
March 13, 2020 08:00 ET
|
Biofrontera AG
Leverkusen, Germany, March 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with...
European Commission approves use of Ameluz® for the treatment of actinic keratosis on extremities and trunk/neck
March 10, 2020 11:00 ET
|
Biofrontera AG
Leverkusen, Germany, March 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results
November 06, 2019 05:30 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...